GlassScriptPhysician profile
Lisa Nguyen
NPI 1780383794
$3,570.36
in general payments reported to CMS, 2019-2025
34 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $934 · 2024: $2,477 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,160 · Education: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,160.38 |
| Education | $409.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $388.40 | 2024 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $271.81 | 2023-2025 | Calquence, Imfinzi, Enhertu |
| Sobi, INC | $235.31 | 2023-2024 | |
| Glaxosmithkline, LLC. | $234.01 | 2024 | Jemperli, Ojjaara |
| Pharmacosmos Therapeutics INC. | $200.31 | 2023-2024 | Monoferric |
| Takeda Pharmaceuticals U.S.A., INC. | $196.43 | 2023-2025 | Fruzaqla, Alunbrig |
| Jazz Pharmaceuticals INC. | $179.56 | 2024 | |
| Karyopharm Therapeutics INC. | $162.48 | 2023-2024 | Xpovio |
| Myriad Genetic Laboratories, INC. | $156.12 | 2024 | Myrisk |
| Eisai INC. | $146.85 | 2023-2024 | |
| Tersera Therapeutics LLC | $130.09 | 2024-2025 | Zoladex, Xermelo |
| Daiichi Sankyo INC. | $121.26 | 2024 | Enhertu, Vanflyta |
| Exelixis INC. | $116.06 | 2023-2024 | Cabometyx |
| Abbvie INC. | $110.68 | 2023-2024 | |
| Astellas Pharma US INC | $108.83 | 2024-2025 | Padcev |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $107.61 | 2023-2024 | Onivyde, Somatuline Depot |
| Incyte Corporation | $82.20 | 2023-2024 | Jakafi |
| Lilly USA, LLC | $79.56 | 2023-2024 | Verzenio, Retevmo, Jaypirca |
| Seagen INC. | $74.99 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $58.13 | 2023 | Imbruvica |
| Pfizer INC. | $49.01 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $47.24 | 2024-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $34.72 | 2024 | Opdualag |
| Dendreon Pharmaceuticals LLC | $33.97 | 2024 | Provenge |
| Pharmaessentia USA Corporation | $31.84 | 2023 | Besremi |
| Cti Biopharma Corp. | $29.91 | 2023 | Vonjo |
| Urogen Pharma, INC. | $27.58 | 2024 | |
| Alexion Pharmaceuticals, INC. | $26.76 | 2023 | Ultomiris |
| Array Biopharma INC | $25.95 | 2024 | Tukysa, Braftovi, Mektovi |
| Deciphera Pharmaceuticals INC. | $24.98 | 2023 | Qinlock |
| G1 Therapeutics, INC. | $24.09 | 2023 | Cosela |
| Boston Scientific Corporation | $22.58 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Genmab U.S., INC. | $17.43 | 2023 | Tivdak |
| Adaptive Biotechnologies Corporation | $13.61 | 2023 | Clonoseq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.